Expression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy
Understanding the prevalence of CD47 expression in hematolymphoid neoplasms is crucial for identifying potential therapeutic targets and selecting patients who may benefit from CD47-targeted therapies. Additionally, CD47 may serve as a valuable diagnostic marker in neoplasms such as Burkitt lymphoma.
Authors
- Yasodha Natkunam (ORCID: https://orcid.org/0000-0002-9816-1018)
- Adnan Mansoor (ORCID: https://orcid.org/0000-0002-6902-3935)
- Sebastian Fernandez‐Pol (ORCID: https://orcid.org/0000-0002-0428-0199)
- Philip L. Bulterys (ORCID: https://orcid.org/0000-0003-1382-743X)
- Jingjing Zhang (ORCID: https://orcid.org/0000-0001-7287-2842)
- Shuchun Zhao (ORCID: https://orcid.org/0000-0002-0562-6817)
- Sheren F Younes (ORCID: https://orcid.org/0000-0002-8961-3043)
Institutions
- University of Calgary (CA)
- University of Colorado Anschutz Medical Campus (US)
- Stanford University (US)
Publication Details
- Journal
- American Journal of Clinical Pathology
- Published
- 2025-03-12
- DOI
- https://doi.org/10.1093/ajcp/aqaf018
- Citations
- 2
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 1.59